Abstract

Patient-Specific iPSC-derived Cardiomyocytes for Drug Development and Toxicity Testing

Ulrich Broeckel, Professor of Pediatrics, Medicine and Physiology - Chief, Section of Genomic Pediatrics, Medical College of Wisconsin

Using iPSC-derived cell types holds the promise to revolutionize drug development and toxicity testing.  In particular, these cells provide a platform to incorporate both phenotypic variability and genetic diversity.  In the presentation, we will discuss the impact of phenotypic and genetic diversity on drug screening and toxicity testing.